Журнал включен в российские и международные библиотечные и реферативные базы данных
РИНЦ (Россия)
RINZ (RUSSIA)
Регистрационное агентство DOI (США)
DOI Registration Agency (USA)
Эко-Вектор (Россия)
Eco-Vector (Russia)
Ulrichsweb (Ulrich’s Periodicals Director

Idiopathic pulmonary fibrosis

DOI: https://doi.org/ 10.29296/25879979-2022-02-04
Download full text PDF
Issue: 
2
Year: 
2022

V.V. Skvortsov, A.N. Gorbach, E.V. Belyakova, E.M. Skvortsova, N.D. Matveyev. Federal State Budgetary Educational Institution of Higher Education «Volgograd state medical university» of the ministry of health of the Russian Federation. e-mail: [email protected]

Idiopathic pulmonary fibrosis is a specific form of chronic lung disease that is characterized by progressive fibrosis of the lung tissue. This disease is сonsidered as a variant of interstitial pneumonia, but has other principles of treatment. The prevalence of this disease in the world varies, averaging 15–20 people per 100,000 populations. Patients complain of progressive shortness of breath, dry cough, discomfort in the chest, muscle weakness, subfebrile fever. According to the clinical history, it is difficult to make an accurate diagnosis due to non-specific complaints of the patient. For instrumental diagnostics, X-ray examination of the lungs, high-resolution computed tomography is used, and a lung tissue biopsy can be performed. Fibrous changes will be observed in the basal and subpleural regions of the lungs, and there will also be an inhomogeneous distribution of the honeycomb zone. As a conservative therapy, the use of the antifibrotic agent pirfenidone is recommended, which demonstrates high efficiency and economic feasibility compared to drugs similar in terms of the main active ingredient.
Keywords: 
idiopathic pulmonary fibrosis
antifibrotic properties
interstitial pneumonia
pirfenidone
nurse
nursing
nursing practice

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Avdeev S.N., Trushenko N.V. Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio Medical advice 2018; 15: 131–136.
  2. Strel’tsov E.A. Safety and efficiency of therapy with modern preparations of idiopathic pulmonary fibrosis Medical Bulletin of the South of Russia 2018; 9(1): 17–22.
  3. Zyryanov S., Butranova O., Shatalova O. Clinical and pharmacological comparison of current antifibrotic drugs for therapy of idiopathic pulmonary fibrosis Pulmonology 2019; 27(6): 789–802.
  4. Leshchenko I.V., Zherebtsov A.D. Idiopathic pulmonary fibrosis: a modern view on pathogenesis and the role of biomarkers RMG 2018; 10(1): 6–10.
  5. Vizel A.A., Belevskiy A., Vizel I. Idiopathic pulmonary fibrosis: on the way of resolving the problem Practical pulmonology 2019; 1: 38–44.
  6. Kardangusheva Aksana M., Sabanchieva Haishat A. Idiopathic pulmonary fibrosis: possibilities of multidisciplinary diagnostic approach Pulmonology 2018; 28 (5): 622–625.
  7. Murkamilov I., Aitbaev K., Fomin V., et al Idiopathic pulmonary fibrosis in the practice of a therapist Bulletin of Science and Practice 2021; 7 (6): 235–249.
  8. Yakovleva O., Klekot A., Hoina-Kardasevich O., et al Discussion issues of fibrotic lung diseases and possibilities of pirfenidone therapy Danish Scientific Journal 2020; 43: 51–57.
  9. Terpigorev S., Belevskiy A. The efficacy and safety of pirfenidone in patients with idiopathic pulmonary fibrosis: data from multicenter and local studies Practical pulmonology 2019; 3: 56–50.
  10. Murkamilov I., Sabirov I., Fomin V., et al Idiopathic pulmonary fibrosis: a contemporary view on the problem of treatment (literature review) The scientific heritage 2020; 50: 21–28.
  11. Murkamilov I., Sabirov I., Fomin V., et al Idiopathic pulmonary fibrosis: a contemporary view on the problem of treatment (literature review) The scientific heritage 2020; 49: 41–48.
  12. Averiyanov A., Sotnikova A. Prospects for cell technology in the treatment of idiopathic pulmonary fibrosis Practical pulmonology 2019; 50: 43–48.
  13. Stepanyan I., Zaitseva A., Shergina E., et al Experience of long-term use of pirfenidone in patients with idiopathic pulmonary fibrosis Clinical Pharmacology and Therapy 2018; 27(4): 77–80.
  14. Avdeev S., Chikina S. Nagatkina O. Idiopathic pulmonary fibrosis: a new international clinical guideline Pulmonology 2019; 29(5): 525–552.
  15. Brovko M., Akulkina L., Sholomova V., et al. Idiopathic pulmonary fibrosis (IPF): a modern approach to classification and diagnosis Clinical Pharmacology and Therapy 2018; 27(2): 43–49.
  16. Arata Azuma Pirfenidone: an antifibrotic drug for the treatment of idiopathic pulmonary fibrosis (IPF) Expert opinion (assessment) in the field of respiratory medicine 2010; 4(3): 301–310.
  17. H. Taniguchi et al. Pirfenidone for idiopathic pulmonary fibrosis European Respiratory Journal 2010; 4: 821–829.
  18. Maher T.M., Strek M.E. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respir Res. 2019 Sep 6; 20(1): 205
  19. Kravtsova O.N., Bagirova G.G. Multiple Coronavirus. Vrach 2021; 32 (5): 5–11.
  20. Kanorsky S.G. Modern treatment of cardiac arrhythmias: comparison of drug and non-drug methods Vrach 2020; 31 (4): 25-33.
  21. Sulima DL, Karev VE, Zhdanov KV Hypertoxic influenza Journal of infectious diseases 2010; 2 (1): 77–79